245 related articles for article (PubMed ID: 36627679)
1. Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and/or housing instability.
Fletcher L; Burrowes SAB; Khan GK; Sabin L; Johnson S; Kimmel SD; Ruiz-Mercado G; Pierre C; Drainoni ML
Harm Reduct J; 2023 Jan; 20(1):4. PubMed ID: 36627679
[TBL] [Abstract][Full Text] [Related]
2. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
[TBL] [Abstract][Full Text] [Related]
3. High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda.
Kennedy CE; Zhao T; Vo AV; Nakubulwa R; Nabakka P; Jackson J; Rosen JG; Chang LW; Reynolds SJ; Quinn TC; Nakigozi G; Kigozi G; Kagaayi J; Nalugoda F; Ddaaki WG; Grabowski MK; Nakyanjo N
AIDS Patient Care STDS; 2023 Jun; 37(6):316-322. PubMed ID: 37294280
[TBL] [Abstract][Full Text] [Related]
4. Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island.
Collins AB; Macon EC; Langdon K; Joseph R; Thomas A; Dogon C; Beckwith CG
J Urban Health; 2023 Oct; 100(5):1062-1073. PubMed ID: 37563518
[TBL] [Abstract][Full Text] [Related]
5. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.
McCrimmon T; Collins LF; Perez-Brumer A; Bazzi AR; Shaffer VA; Kerrigan D; Alcaide ML; Philbin MM
AIDS Patient Care STDS; 2024 Feb; 38(2):61-69. PubMed ID: 38381949
[TBL] [Abstract][Full Text] [Related]
6. Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya.
Kaggiah A; Maina CN; Kinuthia J; Barthold D; Hauber B; Tran J; Simoni JM; Graham SM
BMC Infect Dis; 2024 Apr; 24(1):415. PubMed ID: 38641565
[TBL] [Abstract][Full Text] [Related]
7. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project.
Nguyen N; Lane B; Golub SA; Chastain C; Zucker J; King K; Terry M; Burdge J; Carnevale C; Muscarella A; Castor D; Kutner B; Meyers K
J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26282. PubMed ID: 38965977
[TBL] [Abstract][Full Text] [Related]
8. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
Mantsios A; Murray M; Karver TS; Davis W; Galai N; Kumar P; Swindells S; Bredeek UF; García RR; Antela A; Gomis SC; Bernáldez MP; Czarnogorski M; Hudson K; Walters N; Kerrigan D
BMC Health Serv Res; 2021 Mar; 21(1):255. PubMed ID: 33743684
[TBL] [Abstract][Full Text] [Related]
9. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
[TBL] [Abstract][Full Text] [Related]
10. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
[TBL] [Abstract][Full Text] [Related]
11. Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV.
Matza LS; Paulus TM; Garris CP; Van de Velde N; Chounta V; Deger KA
Patient; 2020 Aug; 13(4):409-422. PubMed ID: 32356146
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
14. Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.
Philbin MM; Parish CL; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):263-270. PubMed ID: 32530905
[TBL] [Abstract][Full Text] [Related]
15. Perceived risks and amelioration of harm in research using mobile technology to support antiretroviral therapy adherence in the context of methamphetamine use: a focus group study among minorities living with HIV.
Pasipanodya EC; Kohli M; Fisher CB; Moore DJ; Curtis B
Harm Reduct J; 2020 Jun; 17(1):41. PubMed ID: 32527276
[TBL] [Abstract][Full Text] [Related]
16. Protocol of a randomized controlled trial to test the effects of client-centered Representative Payee Services on antiretroviral therapy adherence among marginalized people living with HIV.
Olaniyan A; Creasy SL; Batey DS; Brooks MM; Maulsby C; Musgrove K; Hagan E; Martin D; Sashin C; Farmartino C; Hawk M
BMC Public Health; 2020 Sep; 20(1):1443. PubMed ID: 32967646
[TBL] [Abstract][Full Text] [Related]
17. "A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania.
Kerrigan D; Sanchez Karver T; Muraleetharan O; Savage V; Mbwambo J; Donastorg Y; Likindikoki S; Perez M; Gomez H; Mantsios A; Murray M; Beckham SW; Davis W; Galai N; Barrington C
PLoS One; 2020; 15(6):e0234666. PubMed ID: 32530939
[TBL] [Abstract][Full Text] [Related]
18. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
Erguera XA; Koester KA; Diaz Tsuzuki M; Dance KV; Flores R; Kerman J; McNulty MC; Colasanti JA; Collins LF; Montgomery ET; Johnson MO; Sauceda JA; Christopoulos KA
AIDS Behav; 2024 Jul; 28(7):2226-2238. PubMed ID: 38598026
[TBL] [Abstract][Full Text] [Related]
19. Barriers and facilitators to antiretroviral adherence and retention in HIV care among people living with HIV in the Comarca Ngäbe-Buglé, Panama.
Gabster A; Socha E; Pascale JM; Cabezas Talavero G; Castrellón A; Quiel Y; Gantes C; Mayaud P
PLoS One; 2022; 17(6):e0270044. PubMed ID: 35709223
[TBL] [Abstract][Full Text] [Related]
20. A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse.
Kuchinad KE; Hutton HE; Monroe AK; Anderson G; Moore RD; Chander G
BMC Res Notes; 2016 Apr; 9():229. PubMed ID: 27103162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
